Harmonic Discovery

Harmonic Discovery is a computational-experimental drug discovery company designing multi-targeted small molecules, principally kinase inhibitors, whose target profiles are chosen to hit several dysregulated proteins in a cancer at once while avoiding those that cause toxicity. The company argues that rational polypharmacology can be more effective and safer than one-drug-one-target agents. Programmes are preclinical; no sourced financing rounds are recorded here.